Sanofi-Aventis Eyes Summer Launch For Ambien CR
This article was originally published in The Pink Sheet Daily
Executive Summary
Discussions with FDA following an "approvable" letter for the sleep therapy have revolved around labeling for treatment duration, the company says. A summer launch would put Ambien CR's introduction several months behind that of Sepracor's Lunesta, which entered the insomnia market in early April.